Literature DB >> 997586

Metabolism of metoprolol in the rat in vitro and in vivo.

A Arfwidsson, K O Borg, K J Hoffmann, I Skånberg.   

Abstract

1. Metoprolol was metabolized in rat liver microsomes in vitro by O-demethylation with subsequent oxidation and by aliphatic hydroxylation of the methoxy-ethyl substituent and by oxidative deamination of the propanolisopropylamine side-chain. The same routes of metabolism in the rat in vivo were revealed from urinary metabolites. Eight metabolites were identified by g.l.c.-mass spectrometry by comparison with synthetized reference compounds. 2. Metoprolol binds to cytochrome-P-450 eliciting a type I difference spectrum with KS = 23 +/- 2-0 muM. The apparent Michaelis-Menten constant Km = 39 +/- 4-0 muM and Vmax = 1-28 +/- 0-22 nmol/mg protein X min were not significantly affected by pre-treatment of the rats with metoprolol or phenobarbital. Metoprolol pre-treatment had no effect on the cytochrome-P-450 level in the microsomes nor on the rate of metabolism of four standard substrates. Phenobarbital increased the cytochrome P-450 as expected. 3. Four metabolites representing the three main routes of metabolism were quantitatively determined after metabolism with rat liver microsomes and compared with the urinary levels of the same compounds. The same major metabolites were found in vitro and in vivo. The total amount of metabolites was not influenced by pre-treatment with metoprolol or phenobarbital. The relative amounts of the three main metabolites were slightly affected by pre-treatment.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 997586     DOI: 10.3109/00498257609151681

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  8 in total

Review 1.  Metoprolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-11       Impact factor: 9.546

Review 2.  The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

3.  Increased oral clearance of metoprolol in pregnancy.

Authors:  S Högstedt; B Lindberg; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.

Authors:  J C McGourty; J H Silas; M S Lennard; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

5.  Soft drugs. XX. Design, synthesis, and evaluation of ultra-short acting beta-blockers.

Authors:  H S Yang; W M Wu; N Bodor
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

6.  The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites.

Authors:  K J Hoffmann; C G Regårdh; M Aurell; M Ervik; L Jordö
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

7.  Species differences in the metabolism of pamatolol, a cardioselective beta--adrenoceptor antagonist.

Authors:  K J Hoffmann; I Skånberg; K O Borg
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1979       Impact factor: 2.441

8.  Effect of rifampicin on metoprolol and antipyrine kinetics.

Authors:  P N Bennett; V A John; V B Whitmarsh
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.